Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.

NCT02097810 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Solid Tumors
Metastatic Solid Tumors

Interventions

DRUG: Entrectinib

Sponsor

Hoffmann-La Roche